Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Study Summary

The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.

Conditions

Pneumococcal Vaccines

Interventions / Drugs

31 valent pneumococcal conjugate vaccine PCV20 PCV21

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment4049 participants

Primary Completion—

Lead SponsorVaxcyte, Inc.

Data Retrieved2026-04-11 04:24:14.205282+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.